CYP11B2
ENSG00000179142
Target class
Enzyme
Chromosome
8
Approved drugs
1
Clinical candidates (approved and in development)
1
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- Yes
- Target name
- CYP11B2
- Gene name
- Cytochrome P450 family 11 subfamily B member 2
- Gene symbol
- CYP11B2
- Previous gene symbols
- CYP11B
- Protein name
- Cytochrome P450 11B2, mitochondrial (Aldosterone synthase) (ALDOS) (Aldosterone-synthesizing enzyme) (CYPXIB2) (Corticosterone 18-monooxygenase, CYP11B2) (EC 1.14.15.5) (Cytochrome P-450Aldo) (Cytochrome P-450C18) (Steroid 11-beta-hydroxylase, CYP11B2) (EC 1.14.15.4) (Steroid 18-hydroxylase)
- CYP11BL
- CPN2
- P-450C18
- P450aldo
- ALDOS
- Gene biotype
- Protein coding
- Gene family
- Cytochrome P450 family 11
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 1
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 89.37
- Tissue specificity (Gini)
- 0.981
- Tissue specificity (tau)
- 1
- KEGG gene identifiers
- hsa:1585
- Protein interaction confidence
- 0.893676
- Protein interaction partners
- 34
- R-HSA-193993
- R-HSA-194002
- R-HSA-211976
- R-HSA-5579009
- End position
- 142917850
- Start position
- 142910559
- Chromosome
- 8
- Strand
- Reverse
- Mitochondrion inner membrane
- Peripheral membrane protein .
- Mitochondria
- Tissue specificity (tau)
- 0.999943
- Expression inequality (Gini)
- 0.981308
Expression in transcripts per million
- Adrenal Gland
- 89.37
- Testis
- 0.19
- Cervix - Ectocervix
- 0.04
- Spleen
- 0.02
- Liver
- 0.01
Expression in transcripts per million
- Adrenal Gland89.37
- Testis0.19
- Cervix - Ectocervix0.04
- Spleen0.02
- Liver0.01
- Brain - Caudate (basal ganglia)0.01
- Small Intestine - Terminal Ileum0
- Cells - Cultured fibroblasts0
- Breast - Mammary Tissue0
- Nerve - Tibial0
- Uterus0
- Brain - Cerebellar Hemisphere0
- Kidney - Medulla0
- Artery - Aorta0
- Adipose - Visceral (Omentum)0
- Thyroid0
- Pituitary0
- Kidney - Cortex0
- Brain - Frontal Cortex (BA9)0
- Brain - Cortex0
- Ovary0
- Prostate0
- Heart - Atrial Appendage0
- Brain - Substantia nigra0
- Vagina0
And 29 more, listed on the interactive page.
- GO:0002017
- GO:0003091
- GO:0006700
- GO:0006705
- GO:0016125
- GO:0032342
- GO:0032870
- GO:0034651
- GO:0035865
- GO:0055075
- GO:0055078
- GO:0005739
- GO:0005743
- GO:0004507
- GO:0008395
- GO:0020037
Related records
Trials (26)
- A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus
- A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes
- A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.
- A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
- Alternation in the Human Microbiome With Commonly Used Topical Medications
- An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot
- Bioavailability of Levoketoconazole and Ketoconazole Tablets
- Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis
- Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis
- Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia
- Hormonal Mechanisms of Sleep Restriction - Axis Study
- Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women
- ITT4 Intratesticular Hormonal Milieu in Man (ITT4)
- Ketoconazole Foam 2% for the Treatment of Versicolor
- Levoketoconazole Food Effect Study in Healthy Subjects
- Mycological Efficacy and Safety of Ketoconazole 2% Shampoo With a Seven-Day Versus Three-Day Treatment Duration in Pityriasis Versicolor
- Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients
- Open-label Treatment in Cushing's Syndrome
- Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine/Ketoconazole
- Safety and Efficacy of Ketoconazole 2% Foam in the Treatment of Pityrosporum Folliculitis
Drugs (1)
- Levoketoconazole Cytochrome P450 11B2 inhibitor